Development of second primary tumors and outcomes in medulloblastoma by treatment modality: A Surveillance, Epidemiology, and End Results analysis.,Pediatric Blood & Cancer

当前位置： X-MOL 学术 › Pediatr. Blood Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Development of second primary tumors and outcomes in medulloblastoma by treatment modality: A Surveillance, Epidemiology, and End Results analysis.
Pediatric Blood & Cancer ( IF 2.4 ) Pub Date : 2020-05-26 , DOI: 10.1002/pbc.28373
Chonnipa Nantavithya _{1,

2} , Arnold C Paulino ₁ , Kaiping Liao ₃ , Susan L McGovern ₁ , David R Grosshans ₁ , Mary F McAleer ₁ , Kristina D Woodhouse ₁ , Soumen Khatua ₄ , Murali M Chintagumpala _{5,

6} , Nazanin K Majd ₇ , Debra N Yeboa _{1,

3}

Affiliation

As treatment modalities for medulloblastoma have developed and overall survival (OS) has improved, there are relatively limited data on the impact of long‐term effects such as risk of second primary tumors (SPT). To address the knowledge gap, we analyzed factors associated with the risk of SPT and OS by treatment modality for medulloblastoma.

中文翻译：

通过治疗方式在继发性髓母细胞瘤中发展第二原发肿瘤和预后：监测，流行病学和最终结果分析。

随着成髓细胞瘤的治疗方式的发展和总生存期（OS）的提高，关于长期影响的影响（如继发于原发性肿瘤（SPT）的风险）的数据相对有限。为了解决知识鸿沟，我们通过髓母细胞瘤的治疗方式分析了与SPT和OS风险相关的因素。

更新日期：2020-06-23

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11